Sophiris' Drug For Benign Prostatic Hyperplasia Was Well Tolerated Using The Preferred Transrectal Route Of Administration
SAN DIEGO, CA and VANCOUVER, Aug. 31, 2012 /PRNewswire/ - Sophiris Bio Inc. (TSX: SHS) today announced data from its transrectal safety study, in which PRX302, the company's drug candidate for the treatment of Benign Prostatic Hyperplasia (BPH or enlarged prostate), was well tolerated through three months following a transrectal injection. The results support the use of a transrectal ultrasound (TRUS) guided injection for the delivery of PRX302 directly into the prostate. This route of administration will be used in future clinical trials of PRX302 in patients with BPH.
The primary objective of this small study was to evaluate the safety and tolerability of delivering PRX302 via a transrectal route of administration using TRUS. The data allow an assessment as to whether the safety profile from the transrectal delivery was similar to that observed with the transperineal route of administration, which had been used in all previous clinical studies with PRX302.
"The decision to move to a transrectal route of delivering PRX302 directly into the prostate as opposed to transperineal was made based on the input of our advisors and leading urologists treating patients with BPH," said Randall Woods, CEO of Sophiris Bio. "The transrectal route enables PRX302 to be administered by a urologist in an office based setting, in a brief procedure that does not require catheterization. To date 126 patients with BPH have been treated with PRX302 with a similar safety and tolerability profile between the transrectal and transperineal routes of administration."
This ongoing randomized, placebo controlled, double-blind, multicenter, Phase 1-2 study enrolled 40 patients with moderate to severe BPH. Patients were randomized within one of four ascending dose cohorts, and the decision to move to the next higher dose was guided by an independent data monitoring committee that reviewed the safety data through Day 15. The primary endpoint of the study was to evaluate the 3-month safety and tolerability of escalating doses of PRX302, although patients are to continue to be evaluated through Month 12. The data from all four cohorts through Month 3 indicate that PRX302 continues to be well tolerated with an adverse event profile similar to that seen in previous clinical studies using a transperineal injection. No drug-related sexual function adverse events were observed, and there were no reports of bacteremia or sepsis. Improvement in the International Prostate Symptom Score (IPSS) was observed in all cohorts. Given the small sample size of eight patients on PRX302 and two patients on placebo in each cohort, no statistically significant differences were observed.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV